Whalesbook
Margin expansion ne profit mein lagaya 'double engine'!
Viyash Scientific ne Q4 FY26 mein waapas profitability track par aane ka announcement kiya hai, ₹66 crore ka net profit record kiya hai, jo pichle saal ke ₹32 crore ke loss se bilkul alag hai. Is turnaround ka sabse bada reason hai company ke profit margins mein hui zabardast badhotri. Consolidated revenue toh 19% badh kar ₹920 crore ho hi gaya, lekin EBITDA mein toh 64% ki tezi aayi aur woh ₹200 crore pahunch gaya! Yeh EBITDA growth dikhata hai ki company operations ko efficiently manage kar rahi hai aur sahi pricing strategies use kar rahi hai, shayad demand zyada hai aur product mix bhi favourable hai.
Full year FY26 ke results bhi kuch aise hi chamke, net profit 14 guna badh kar ₹225 crore ho gaya aur EBITDA 60% badh kar ₹702 crore pahunch gaya. Company ke CEO, Dr. Hari Babu Bodepudi ne kaha ki merger synergies ko leverage karne par focus hai, jisse operating leverage aur resilience mein izafa ho raha hai. Stock mein bhi Tuesday ko 1% ki halki tezi aayi thi aur woh ₹229 par trade kar raha tha.
Global position aur future ki planning?
Viyash Scientific animal health sector mein duniya ki top 25 companies mein se ek hai. Unka integrated business model, jisme formulations, APIs aur CDMO services dono human aur veterinary markets ke liye shamil hain, diversification offer karta hai. Company apni market position aur technological capabilities ko aur mazboot karne ke liye acquisitions bhi explore kar rahi hai. Strong product pipeline ke saath, Viyash FY27 mein bhi growth maintain karne ka aim kar rahi hai. Jo companies consistently margins expand karti hain, unke stock prices mein bhi sustained increase dekha jaata hai, agar yeh gains sustainable rahen toh. Viyash Scientific ki global manufacturing facilities ko USFDA aur EUGMP jaise bade regulatory bodies ne approve kiya hua hai, jisse unhein important international markets mein access milta hai.
Potential risks aur competition?
Itne positive results ke bawajood, Viyash Scientific ke saamne kuch potential risks bhi hain. Merger synergies par zyada depend karna execution risk laa sakta hai; agar integration mein deri hui toh future growth par impact pad sakta hai. Halanki Net Debt to EBITDA ratio 0.2 times ek healthy balance sheet ka signal de raha hai, lekin aggressive acquisition strategies se debt levels badh sakte hain. Pharmaceutical aur animal health sector mein competition kaafi high hai, aur bade global players ke paas substantial R&D resources hain. Viyash Scientific, global ranking ke bawajood, thode smaller scale par operate karti hai. Iske alawa, global supply chain issues ka dobara ubharna ya regulatory scrutiny mein izafa bhi profitability ko affect kar sakta hai.